{"id":60412,"date":"2024-02-28T06:47:45","date_gmt":"2024-02-28T06:47:45","guid":{"rendered":"https:\/\/medsname.com\/rasalect\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rasalect","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/rasalect\/","title":{"rendered":"Rasalect"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer<\/h3>\n

Rasalect<\/strong> je peror\u00e1ln\u00ed rasagiline<\/strong> (1 mg) tablet \u2014 a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> pou\u017e\u00edvan\u00e1 k l\u00e9\u010db\u011b Parkinson disease<\/strong>. By blocking MAO-B in the brain, it slows the breakdown of dopamine and helps lengthen the time levodopa keeps working between doses (reduces “off” time). Unlike selegiline, rasagiline is ne<\/em> metabolised to amphetamine derivatives, so insomnia is much less of a problem. Common side effects: insomnia, headache, dyskinesia, dry mouth, postural hypotension. D\u016fle\u017eit\u00e9:<\/strong> avoid combination with most antidepressants (SSRIs, SNRIs, TCAs), opioids such as pethidine and tramadol, and dextromethorphan — risk of serotoninov\u00fd syndrom<\/em>.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n

What Is Rasalect?<\/h2>\n

Rasalect is an oral tablet containing rasagiline 1 mg<\/strong>. rasagiline is a selective monoamine oxidase type B (MAO-B) inhibitor<\/strong> originally introduced as Azilect<\/strong>. Rasalect is manufactured by a WHO-GMP certified facility and is bioequivalent to the originator brand at the same strength.<\/p>\n

Rasagiline was developed as a second-generation MAO-B inhibitor specifically to avoid selegiline’s amphetamine metabolites. It has a clean active metabolite (aminoindan) which itself has neuroprotective properties in laboratory models. Rasagiline can be used as monotherapy in early Parkinson disease or as adjunct to levodopa for end-of-dose wearing-off.<\/p>\n

How Does Rasalect (rasagiline) Work?<\/h2>\n

Rasagiline irreversibly inactivates MAO-B in the brain, slowing the breakdown of dopamine. Like selegiline it is selective for MAO-B at therapeutic doses (1 mg\/day) but loses selectivity above 1.5–2 mg\/day. Its main metabolite, aminoindan, has its own potential neuroprotective activity in preclinical models — the basis for the ADAGIO disease-modification trial, which produced suggestive but not conclusive results.<\/p>\n

Comparing the MAO-B Inhibitors<\/h2>\n

The three MAO-B inhibitors used in Parkinson disease — selegiline, rasagiline and safinamide — share a common mechanism but differ meaningfully in metabolites, dosing and clinical positioning:<\/p>\n\n\n\n\n\n\n\n\n\n
Vlastnost<\/th>\nSelegiline<\/th>\nRasagiline<\/th>\nSafinamide<\/th>\n<\/tr>\n<\/thead>\n
Typical dose<\/td>\n5–10 mg\/day<\/td>\n0.5–1 mg\/day<\/td>\n50–100 mg\/day<\/td>\n<\/tr>\n
Active metabolites<\/td>\nAmphetamine + methamphetamine<\/td>\nAminoindan (non-amphetamine)<\/td>\nNo active stimulant metabolite<\/td>\n<\/tr>\n
Glutamate effect<\/td>\nNe<\/td>\nNe<\/td>\nAno<\/strong> — sodium-channel\/glutamate-release modulation<\/td>\n<\/tr>\n
Indikace<\/td>\nMonotherapy or adjunct<\/td>\nMonotherapy or adjunct<\/td>\nAdjunct only<\/strong> — for fluctuating PD on levodopa<\/td>\n<\/tr>\n
Insomnia risk<\/td>\nHigher (amphetamine metabolites)<\/td>\nLow<\/td>\nLow<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Who Is Rasalect For?<\/h2>\n

Rasalect is appropriate for adults with Parkinson disease — either as monotherapy in early disease or as adjunct to levodopa in patients with motor fluctuations. Compared with selegiline, rasagiline is preferred when insomnia is a concern. Compared with safinamide, rasagiline is the better monotherapy option (safinamide is licensed only as adjunct).<\/p>\n

Dosing and Administration<\/h2>\n

The standard adult dose is 1 mg once daily<\/strong>, taken in the morning with or without food. There is no need for titration — full effect is reached within 1–2 weeks. Doses above 1 mg\/day are generally avoided as MAO-B selectivity is lost. In moderate hepatic impairment reduce to 0.5 mg\/day; in severe hepatic impairment avoid.<\/p>\n\n\n\n\n\n\n\n
Populace<\/th>\nD\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Standard adult<\/td>\n1 mg once daily, morning<\/td>\n<\/tr>\n
Lehk\u00e9 po\u0161kozen\u00ed jater<\/td>\n0.5 mg once daily<\/td>\n<\/tr>\n
Moderate-severe hepatic impairment<\/td>\nVyhnout se<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
⚠ Tyramine and the “cheese effect”<\/strong> At standard MAO-B-selective doses, dietary tyramine restriction is generally ne<\/em> required. However, MAO-B selectivity is dose-dependent — selegiline above 10 mg\/day, rasagiline above 1 mg\/day, and safinamide above 100 mg\/day lose selectivity and inhibit peripheral MAO-A as well. At those doses, tyramine-rich foods (aged cheeses, cured meats, broad beans, fermented soya, draught beer) can trigger a hypertensive crisis. Stay within prescribed doses to avoid this risk.<\/div>\n

B\u011b\u017en\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n

Headache (the most common — usually transient), arthralgia, dyspepsia, depression, postural hypotension, flu-like symptoms. Less common: hallucinations, insomnia (much less than selegiline), weight loss, falls. With levodopa: increased dyskinesia.<\/p>\n

⚠ Serotonin syndrome — dangerous interactions<\/strong> Combining a MAO-B inhibitor with serotonergic drugs can cause serotoninov\u00fd syndrom<\/em>: agitation, sweating, tremor, hyperreflexia, fever, diarrhoea, in severe cases seizures and death. Avoid:<\/strong> SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram), SNRIs (venlafaxine, duloxetine), tricyclics (amitriptyline, imipramine), pethidine (meperidine), tramadol, dextromethorphan, methadone, St John’s wort, MDMA. Wash-out periods:<\/strong> stop fluoxetine 5 weeks before starting MAO-B inhibitor; stop other SSRIs\/SNRIs at least 2 weeks before; do not start fluoxetine within 2 weeks of stopping the MAO-B inhibitor.<\/div>\n

Drug and Food Interactions<\/h2>\n